Skip to content

CATALYST PHARMACEUTICALS, INC.: 10-K filed 2019-03-18

What CATALYST PHARMACEUTICALS, INC. reported in its annual report filed 2019-03-18 (fiscal FY 2018): 37 published measures, 90 facts as tagged in accession 0001193125-19-078253.

This filing

Form
10-K (annual report)
Filed
2019-03-18
Fiscal period
fiscal FY 2018
Accession
0001193125-19-078253 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CATALYST PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-12-3160,449,962USD
At 2017-12-3185,387,430USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-12-319,666,153USD
At 2017-12-314,423,618USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-12-3150,783,809USD
At 2017-12-3180,963,812USD
At 2016-12-3139,308,930USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-12-3116,559,400USD
At 2017-12-3157,496,702USD
At 2016-12-3113,893,064USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-10-01 to 2018-12-31-14,499,609USD92
2018-01-01 to 2018-12-31-34,003,514USD365
2018-07-01 to 2018-09-30-7,838,873USD92
2018-04-01 to 2018-06-30-5,965,140USD91
2018-01-01 to 2018-03-31-5,699,892USD90
2017-10-01 to 2017-12-31-5,387,698USD92
2017-01-01 to 2017-12-31-18,412,377USD365
2017-07-01 to 2017-09-30-4,177,649USD92
2017-04-01 to 2017-06-30-3,879,901USD91
2017-01-01 to 2017-03-31-4,967,129USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-25,704,406USD365
2017-01-01 to 2017-12-31-13,742,572USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-01-01 to 2018-12-3192,018USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2018-10-01 to 2018-12-31500,000USD92
2018-01-01 to 2018-12-31500,000USD365
2017-01-01 to 2017-12-310USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-12-31293,115USD365
2017-01-01 to 2017-12-3157,350,168USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-15,526,011USD365
2017-01-01 to 2017-12-31-3,958USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-12-31-160,563,961USD
At 2017-12-31-126,560,447USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-12-31245,425USD
At 2017-12-31191,385USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-12-313,550,644USD365
2017-01-01 to 2017-12-312,407,961USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-10-01 to 2018-12-31-14,843,267USD92
2018-01-01 to 2018-12-31-35,295,165USD365
2018-07-01 to 2018-09-30-8,182,603USD92
2018-04-01 to 2018-06-30-6,335,855USD91
2018-01-01 to 2018-03-31-5,933,440USD90
2017-10-01 to 2017-12-31-5,511,786USD92
2017-01-01 to 2017-12-31-18,679,636USD365
2017-07-01 to 2017-09-30-4,306,708USD92
2017-04-01 to 2017-06-30-4,181,271USD91
2017-01-01 to 2017-03-31-4,679,871USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-12-3155,187,406USD
At 2017-12-3185,187,157USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-12-319,511,354USD
At 2017-12-314,266,162USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-12-312,337,367USD
At 2017-12-311,945,575USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-01-01 to 2018-12-3135,795,165USD365
2017-01-01 to 2017-12-3118,679,636USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2018-12-3156,012USD
At 2017-12-310USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-01-01 to 2018-12-3119,919,204USD365
2017-01-01 to 2017-12-3111,375,237USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-12-31102,739,257shares
At 2017-12-31102,549,498shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-12-31211,265,279USD
At 2017-12-31207,421,710USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-12-31-20,248USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2018-12-31442,572USD
At 2017-12-31350,554USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-12-31197,147USD
At 2017-12-31159,169USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-12-317,173,987USD
At 2017-12-312,320,587USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-12-311,649,781USD
At 2017-12-311,173,744USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2018-12-310USD
At 2017-12-310USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-34,003,514USD365
2017-01-01 to 2017-12-31-18,412,377USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-34,003,514USD365
2017-01-01 to 2017-12-31-18,412,377USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-34,023,762USD365
2017-01-01 to 2017-12-31-18,412,377USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-01-01 to 2018-12-3115,875,961USD365
2017-01-01 to 2017-12-317,304,399USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-01-01 to 2018-12-3137,978USD365
2017-01-01 to 2017-12-3145,689USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2018-01-01 to 2018-12-311,291,651USD365
2017-01-01 to 2017-12-31454,163USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-3156,012USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-31391,792USD365
2017-01-01 to 2017-12-311,012,399USD365

Inspect the source

Entity
CATALYST PHARMACEUTICALS, INC. / CIK 0001369568
Captured
2026-09-21T17:19:25.463Z
SEC response SHA-256
7cf76a511a9127dd31ed7d53955bbe348f790d8d7fd354d359e6674e7b2af9c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001369568.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))